FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and medicine, in particular to a method for selective expression of a target polynucleotide in retinal pigment epithelial cells of a human subject in need thereof, comprising administering to a subject a sub-retinal injection rAAV2/5 vector containing a polynucleotide under the control of a CAG promoter, thereby transducing retinal pigment epithelial cells.
EFFECT: invention enables improving vision in patients with disorders.
13 cl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
| VIRIONS OF AN ADENO-ASSOCIATED VIRUS WITH A VARIANT CAPSID AND METHODS FOR USING THEM | 2017 |
|
RU2742724C1 |
| CODON-OPTIMIZED COMPLEMENT FACTOR I | 2019 |
|
RU2824048C2 |
| VIRIONS OF ADENO-ASSOCIATED VIRUS WITH OPTIONAL CAPSID AND METHODS OF THEIR USE | 2012 |
|
RU2611202C2 |
| COMPLEMENT FACTOR I AND COMPLEMENT FACTOR I COFACTOR, VECTORS ENCODING THEM AND USE FOR THERAPEUTIC PURPOSES | 2019 |
|
RU2809247C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2746991C2 |
| GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
| AAV VECTORS | 2018 |
|
RU2793112C2 |
| TREATMENT OF RETINITIS PIGMENTOSA | 2016 |
|
RU2737049C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IV A | 2019 |
|
RU2794960C2 |
